Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 entities : Gilead sciences, inc. save search
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Published: 2023-10-03 (Crawled : 13:30) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.2%
H: 0.9%
C: 0.08%
covid-19 hiv
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Published: 2023-08-24 (Crawled : 18:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.27%
H: 1.15%
C: -1.19%
covid-19 veklury fda treat
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-07-14 (Crawled : 14:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.13%
H: 1.34%
C: 0.76%
covid-19 veklury fda renal treatment dialysis
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-05-26 (Crawled : 09:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.45%
H: 0.79%
C: -1.17%
covid-19 veklury chmp renal positive dialysis
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 2.59%
H: 0.72%
C: 0.63%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
IOVA M | $11.32 -3.41% -3.53% 5.3M
|
Health Technology
|
| O: 6.12%
H: 4.99%
C: 4.21%
INO 3 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 5.5%
H: 4.35%
C: 3.48%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 1.43%
H: 0.36%
C: -1.08%
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 2.58%
H: 23.12%
C: 20.85%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: 0.0%
H: 7.14%
C: 5.71%
covid-19 research global immunotherapy report impact technology market
Pediatric Health Market Research Report by Type, Therapeutics, Treatment, Treatment Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-03 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -1.02%
H: 2.67%
C: 0.18%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: 0.0%
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.13%
H: 0.63%
C: 0.53%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.42%
H: 0.59%
C: -0.04%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.43%
H: 0.41%
C: 0.25%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.4%
H: 2.75%
C: 1.52%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.72%
H: 1.29%
C: 1.04%
covid-19 treatment research global report impact health market
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Published: 2022-09-16 (Crawled : 11:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
covid-19 veklury treatment chmp positive
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.0%
H: 27.62%
C: 14.36%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.72%
H: 0.41%
C: 0.18%
covid-19 treatment lenzilumab publication
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
Published: 2022-04-04 (Crawled : 07:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.01%
H: 1.97%
C: 1.67%
covid-19 treatment fda review
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published: 2022-03-15 (Crawled : 16:00) - prnewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.47%
H: 0.62%
C: -0.18%
covid-19 viral drug treatment drug covid therapy antiviral
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment
Published: 2022-02-15 (Crawled : 14:00) - prnewswire.com
NRXP 1 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 1.66%
H: 9.15%
C: -0.65%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.01%
H: 0.65%
C: 0.35%
covid-19 zyesami aviptadil health als covid yes enroll
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
covid-19 treatment europe risk oxygen covid disease
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published: 2021-12-07 (Crawled : 10:00) - globenewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
europe covid covid-19
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Published: 2021-12-06 (Crawled : 15:00) - globenewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
approval covid chmp covid-19
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Published: 2021-09-22 (Crawled : 14:00) - biospace.com/
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.47%
H: 0.15%
C: -0.96%
covid risk covid-19
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.